Scientists have developed a spit test that can be taken at home and is more accurate than the one currently used by the NHS - peakSTOCK/iStockphoto A simple saliva test can identify men who are most ...

A simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown. The PSA blood test checks the level of prostate-specific antigen, a marker for ...

A new at-home spit test for prostate cancer may be better than current blood tests, a new study shows. The simple saliva test has been developed by experts and works by analysing genetic variants in a ...

Another problem with the PSA test is that an elevated or fast-rising PSA reading can indicate the presence of cancer, but can also be caused by something minor, such as an infection or an enlarged ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford ...

WASHINGTON (AP) _ Almost a third of men over 75 undergo laboratory blood tests each year to check their prostate health, but a new study questions the value of using the PSA test to screen men that ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

Patrick Shannon of Kenhorst was relishing a new phase of life — retirement from his careers in construction and security — when his primary care doctor called with unexpected news. Shannon’s recent ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the ...